Biodexa Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Biodexa Pharmaceticals
BDRX Stock   2.33  0.02  0.85%   
Biodexa Pharmaceticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Biodexa Pharmaceticals' valuation are provided below:
Gross Profit
-4.9 M
Market Capitalization
2 M
Enterprise Value Revenue
4.6966
Revenue
83 K
Earnings Share
(26.79)
We have found one hundred twenty available fundamental signals for Biodexa Pharmaceticals, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Biodexa Pharmaceticals prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Enterprise Value is likely to rise to about 23.1 M in 2026, whereas Market Cap is likely to drop slightly above 13.6 M in 2026.

Biodexa Pharmaceticals Total Revenue

0.0

Check Biodexa Pharmaceticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biodexa Pharmaceticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 100 K, Selling General Administrative of 4 M or Other Operating Expenses of 11.7 M, as well as many indicators such as Price To Sales Ratio of 0.47, Dividend Yield of 0.0 or PTB Ratio of 3.12. Biodexa financial statements analysis is a perfect complement when working with Biodexa Pharmaceticals Valuation or Volatility modules.
  
Build AI portfolio with Biodexa Stock
Check out the analysis of Biodexa Pharmaceticals Correlation against competitors.
For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.

Biodexa Pharmaceticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets20.2 M13.3 M21.6 M
Very volatile
Other Current Liabilities2.6 M2 M3.3 M
Slightly volatile
Total Current Liabilities3.8 M4.5 M4.8 M
Pretty Stable
Property Plant And Equipment Net277 K291.6 K1.2 M
Slightly volatile
Accounts Payable826.8 K636.3 K984 K
Slightly volatile
Cash1.4 M1.5 M7.3 M
Pretty Stable
Non Current Assets Total10.4 M5.4 M11 M
Pretty Stable
Other Assets3.2 M3 M1.5 M
Slightly volatile
Cash And Short Term Investments1.4 M1.5 M7.3 M
Pretty Stable
Non Current Liabilities Total1.9 M1.3 M2.3 M
Slightly volatile
Other Current Assets7.8 M7.4 M2.6 M
Slightly volatile
Other Stockholder Equity63.1 M113.9 M55.7 M
Slightly volatile
Total Liabilities5.8 M5.8 M7.1 M
Slightly volatile
Total Current Assets9.8 M7.9 M10.5 M
Very volatile
Intangible Assets7.2 M5.1 M6.6 M
Very volatile
Short and Long Term Debt Total621.6 K654.3 K2.2 M
Slightly volatile
Net Receivables584.7 K643.5 K616.4 K
Pretty Stable
Liabilities And Stockholders Equity21.8 M13.3 M22.2 M
Very volatile
Accumulated Other Comprehensive Income54.1 M61 M41.5 M
Slightly volatile
Short Term Debt343 K548.1 K575.3 K
Slightly volatile
Common Stock8.1 M7.7 M1.4 M
Slightly volatile
Net Tangible Assets8.9 M12 M8.3 M
Slightly volatile
Common Stock Shares Outstanding748.1 K712.5 K122.4 K
Slightly volatile
Capital Lease Obligations517.2 K654.3 K903.3 K
Slightly volatile
Net Invested Capital7.7 M7.5 M17.3 M
Slightly volatile
Property Plant And Equipment Gross2.5 M1.4 M5.3 M
Slightly volatile
Capital Stock8.1 M7.7 M1.5 M
Slightly volatile
Net Working Capital4.3 M3.4 M6.6 M
Slightly volatile
Property Plant Equipment1 M1 M1.7 M
Slightly volatile
Other Liabilities40 K45 K49.1 K
Slightly volatile
Current Deferred Revenue1.8 M1.7 M411.6 K
Slightly volatile

Biodexa Pharmaceticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization100 K105.3 K717.5 K
Pretty Stable
Selling General Administrative4 M4.4 M3.5 M
Slightly volatile
Other Operating Expenses11.7 M10.6 M9.9 M
Slightly volatile
Research Development7.5 M6.3 M6.2 M
Slightly volatile
Total Operating Expenses4.9 M3.4 M5.6 M
Very volatile
Interest Expense123.1 K148.5 K163.1 K
Slightly volatile
Selling And Marketing Expenses5.1 K5.4 K273.9 K
Slightly volatile
Cost Of Revenue4.7 M4.9 M4 M
Slightly volatile
Reconciled Depreciation217.2 K228.6 K929.2 K
Slightly volatile

Biodexa Pharmaceticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation217.2 K228.6 K749.6 K
Very volatile
Capital Expenditures399 K696.6 K473.9 K
Very volatile
End Period Cash Flow1.4 M1.5 M7.3 M
Pretty Stable
Begin Period Cash Flow8 M5.4 M7.8 M
Pretty Stable
Issuance Of Capital Stock6.9 M7.5 M11.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.470.4959.1148
Slightly volatile
Days Sales Outstanding428776432
Pretty Stable
Capex To Depreciation2.882.741.2044
Slightly volatile
Payables Turnover9.036.927.59
Slightly volatile
Sales General And Administrative To Revenue9.313.119.6237
Pretty Stable
Research And Ddevelopement To Revenue16.5712.2815.4788
Pretty Stable
Capex To Revenue1.180.790.9085
Pretty Stable
Cash Per Share2.943.115.9 M
Slightly volatile
Days Payables Outstanding51.8554.584.2 K
Slightly volatile
Income Quality2.021.931.0493
Slightly volatile
Intangibles To Total Assets0.270.340.2542
Pretty Stable
Current Ratio3.362.012.6755
Pretty Stable
Receivables Turnover0.460.493.2177
Very volatile
Debt To Equity0.09540.11.1248
Slightly volatile
Capex Per Share1.361.44960.7 K
Slightly volatile
Revenue Per Share1.3 K1.4 K1.2 M
Pretty Stable
Interest Debt Per Share1.281.355.7 M
Slightly volatile
Debt To Assets0.05370.05660.2063
Slightly volatile
Operating Cycle669703580
Very volatile
Days Of Payables Outstanding51.8554.584.2 K
Slightly volatile
Ebt Per Ebit1.10.751.0089
Slightly volatile
Effective Tax Rate0.04570.04810.1107
Slightly volatile
Total Debt To Capitalization0.170.09240.2683
Slightly volatile
Debt Equity Ratio0.09540.11.1248
Slightly volatile
Quick Ratio3.342.012.6671
Pretty Stable
Net Income Per E B T0.710.860.8746
Very volatile
Cash Ratio0.360.381.8569
Very volatile
Days Of Sales Outstanding428776432
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.171.221.0763
Pretty Stable
Fixed Asset Turnover0.420.60.4792
Slightly volatile
Debt Ratio0.05370.05660.2063
Slightly volatile
Price Sales Ratio0.470.4959.1148
Slightly volatile
Asset Turnover0.03310.03250.0378
Slightly volatile

Biodexa Pharmaceticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap13.6 M23.1 M14.9 M
Slightly volatile

Biodexa Fundamental Market Drivers

Biodexa Upcoming Events

26th of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Biodexa Pharmaceticals Financial Statements

Biodexa Pharmaceticals investors use historical fundamental indicators, such as Biodexa Pharmaceticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biodexa Pharmaceticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.7 M1.8 M
Cost Of Revenue4.9 M4.7 M
Stock Based Compensation To Revenue 0.07  0.07 
Sales General And Administrative To Revenue 13.11  9.30 
Research And Ddevelopement To Revenue 12.28  16.57 
Capex To Revenue 0.79  1.18 
Revenue Per Share1.4 K1.3 K
Ebit Per Revenue(18.93)(19.88)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft

Additional Tools for Biodexa Stock Analysis

When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY